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Clinical Guidelines for the Management of Craniofacial Fibrous Dysplasia
Abstract
Fibrous dysplasia (FD) is a non-malignant condition caused by post-zygotic, activating mutations of the
GNAS gene that results in inhibition of the differentiation and proliferation of bone-forming stromal cells
and leads to the replacement of normal bone and marrow by fibrous tissue and woven bone. The
phenotype is variable and may be isolated to a single skeletal site or multiple sites and sometimes is
associated with extraskeletal manifestations in the skin and/or endocrine organs (McCune-Albright
syndrome). The clinical behavior and progression of FD may also vary, thereby making the management
of this condition difficult with few established clinical guidelines. This paper provides a clinically-focused
comprehensive description of craniofacial FD, its natural progression, the components of the diagnostic
evaluation and the multi-disciplinary management, and considerations for future research.
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craniofacial fibrous dysplasia
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From International Meeting on Fibrous Dysplasia/McCune-Albright Syndrome and Cherubism: Best Clinical
Practice and Future Research
Bethesda, MD, USA. 3-5 October 2010

Abstract
Fibrous dysplasia (FD) is a non-malignant condition caused by post-zygotic, activating mutations of the GNAS gene
that results in inhibition of the differentiation and proliferation of bone-forming stromal cells and leads to the
replacement of normal bone and marrow by fibrous tissue and woven bone. The phenotype is variable and may
be isolated to a single skeletal site or multiple sites and sometimes is associated with extraskeletal manifestations
in the skin and/or endocrine organs (McCune-Albright syndrome). The clinical behavior and progression of FD may
also vary, thereby making the management of this condition difficult with few established clinical guidelines. This
paper provides a clinically-focused comprehensive description of craniofacial FD, its natural progression, the
components of the diagnostic evaluation and the multi-disciplinary management, and considerations for future
research.
Definition
Fibrous dysplasia (FD) is a non-malignant condition in
which normal bone and marrow are replaced by fibrous
tissue and haphazardly distributed woven bone [1,2].
Patients may exhibit involvement of one bone (monostotic
FD; MFD), multiple bones (polyostotic FD; PFD) or they
may have McCune-Albright syndrome (MAS), which has
been classically defined by the triad of PFD, café-au-lait
skin macules and endocrinopathies, including among
others, precocious puberty [3]. FD is caused by somatic
activating mutations in the a subunit of the stimulatory G
protein encoded by the gene GNAS [4,5]. A related disorder, cherubism, is manifest by expansile, multiloculated,
radiolucent fibro-osseous lesions with multiple giant cells
located bilaterally and symmetrically in the jaws. Cherubism is genetically distinct from FD and will be discussed
elsewhere in the Proceedings of this meeting.
Prevalence
MFD is reported to be the most common manifestation
of the disease, in some references it is estimated to occur
1
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four times more often than PFD [6]. However, in other
series PFD is reported to be more common than MFD
[7,8]. While the prevalence of MFD is probably greater
than PFD, in none of the studies that define the relative
prevalence of MFD versus PFD have the subjects undergone thorough skeletal and/or endocrine screening to
determine the full extent of the skeletal and/or endocrine
involvement. The most common locations are the craniofacial bones, proximal femur, and rib [2,8-11]. In MFD,
the zygomatic-maxillary complex is reported to be the
region most commonly involved (Figure 1A&B) [12]. In
the less prevalent PFD and MAS, the craniofacial region
is involved in 90% of the cases and the anterior cranial
base is involved in over 95% of cases. (Figure 2) [13].
Depending on the type and location of FD, the signs and
symptoms vary and include facial deformity and asymmetry, vision changes, hearing impairment, nasal congestion
and/or obstruction, pain, paresthesia, and malocclusion.
Many patients are asymptomatic and the diagnosis is
made when a family member, friend or health care provider who has not seen the patient for a period of time
notices asymmetry, or there is an incidental abnormality
noted on dental or panoramic x-rays or on a head and
neck computed tomogram (CT).

© 2012 Lee et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
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Figure 1 An 11-year old female with monostotic fibrous dysplasia of the left zygomatic-maxillary region. A-C) Clinical photographs
demonstrating the appearance. The lesion was quiescent and asymptomatic. It had grown slowly over a period of years. D) Her dentist noted
delayed eruption of her teeth (*) on that side as well as mild facial asymmetry and obtained the panorex that identified the lesion. E-I) CT
images demonstrate the pathognomonic appearance of FD for her age, a homogenous, “ground-glass” lesion. J) The reconstructed CT image
gives a sense of the three dimensional shape of the lesion that accounts for the clinical appearance.
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Figure 2 Extensive fibrous dysplasia involvement of the cranial base in a patient with MAS. In patients with PFD or MAS, the anterior cranial
base is involved in 95% of the cases as seen in this CT image.

Natural progression and clinical behavior

FD most commonly behaves as a slow and indolent growing mass lesion. The facial deformity and distortion of
adjacent structures such as optic nerve, eye/globe, nasal
airway, cranial nerve VII, middle ear ossicles, and teeth are
gradual and insidious. Uncommonly, in young children
and pre-pubertal adolescents, the lesions may demonstrate
rapid growth, cortical bone expansion and displacement of
adjacent structures such as the eye and the teeth. In some
patients, rapid growth is associated with other pathological
lesions such as aneurysmal bone cysts (ABC) or mucoceles
(Figure 3) [13-15], or more rarely with malignant transformation. Malignant change to osteosarcoma or other forms
of sarcoma has been reported to occur in less than 1% of
cases of FD [16-22].
When rapid enlargement occurs, adjacent vital structures, such as the optic nerve, globe and auditory canal/
structures and nasal airway may be invaded or compressed, resulting in functional deficits. For these reasons,

some authors have advocated aggressive surgical resection
to avoid potential blindness or hearing loss [23-26]. Rapid
enlargement of FD in the nasal bones, maxilla or mandibular symphysis may result in airway obstruction by obliteration of the nasal cavity or by posterior displacement of
the tongue. However, it has recently been demonstrated
that such aggressive behavior with rapid expansion is the
exception and that a conservative expectant approach is
more prudent [13,14,27].
In MFD and PFD, progression of the lesions appears
to taper off as the patients approach puberty (defined as
skeletal maturity throughout this article) and beyond.
Although continued active disease and symptoms into
adulthood are uncommon, they have been reported
[28-30]. In addition, in the NIH Screening and Natural
History Study of Fibrous Dysplasia (SNHFD, protocol
98-D-0145) has documented persistent active disease
and pain into adulthood in some patients. Based on >25
years of observation at the NIH, it appears that MFD,
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Figure 3 Fibrous dysplasia with a secondary aneurysmal bone cyst (ABC). A) The patient with a history of MAS complained of visual changes.
Worsening asymmetry of the left eye and face was noted, and an on examination he was noted to have vertical dystopia of the orbit in the
preoperative photograph. He was found to have a rapidly growing ABC within FD and underwent immediate resection and decompression of
the ABC. B) The asymmetry and symptoms resolved after surgery. Note the classic café au lait spots of the left face and neck region as part of
the triad of MAS. C&D) Preoperative CT images of the patient in A showing the FD lesion and associated ABC. Note the fluid/fluid level
diagnostic of an ABC (arrows). The association of an ABC often results in aggressive behavior and rapid enlargement of the FD lesion with
displacement of adjacent structures, in this case, the eye.
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does not progress to PFD and neither progress to MAS
[31].
In MAS, while growth of the lesions may also diminish
after puberty, the overall degree of bony enlargement and
deformity is often more severe and disfiguring than in
patients with PFD. Data in the literature and observations
by the NIH SNHFD indicate that the most severe deformities and symptoms occur in patients who have poorly
controlled growth hormone excess [32-34]. It is recommended, therefore, that growth hormone excess in
patients with PFD and MAS be aggressively managed.
In a retrospective study of 266 serial bone scans from
66 patients followed for up to 32 years in patients with
extensive PFD or MAS, Hart et al. demonstrated that
90% of FD lesions, regardless of the site, were present
prior to 15 years of age [31]. In the craniofacial region,
90% of all the lesions were detectable by bone scan by
age 3.4, and no new lesions in the craniofacial region are
very reported beyond the age of 10.

Diagnosis and work-up
Medical history and examination

A thorough history and physical examination are necessary to determine the extent of disease and to determine
whether the FD is isolated or one of multiple lesions
associated with PFD or MAS. Documentation of the
onset and types of symptoms, presence of functional
impairments and duration are imperative. Inquiries
should include onset of menarche in females (to rule-out
precocious puberty), other endocrine abnormalities or
pathologies (such as hyperthyroidism, pituitary abnormalities, and renal phosphate wasting), growth abnormalities (review of growth charts), and history of fractures
(to rule-out the presence of other FD lesions in the extremities) as well as the presence of skin lesions (café- aulait lesions). These questions are particularly critical in
young patients where underlying endocrine abnormalities
may not have been detected and aggressive management
is warranted. If there are any positive responses to the
above inquiries, a referral to an endocrinologist is
strongly recommended to rule out PFD or MAS. A skeletal survey or bone scan may be indicated if there is a suspicion of PFD or MAS, particularly in a patient that is
not skeletally mature. Additional FD lesions beyond the
craniofacial region require further evaluation by an
orthopedic surgeon.
If the symptoms include rapid expansion, new onset of
pain, visual change or loss, hearing change or loss, evidence of airway obstruction, new onset of paresthesia or
numbness, a referral to a surgical specialist should be
made immediately. Appropriate specialists that may be
consulted include: neurosurgeons, craniofacial surgeons,
oral & maxillofacial surgeons, otolaryngologists, neuroophthalmologists, audiologists and dentists, depending
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on the site of involvement or symptoms. In institutions
where a craniofacial anomalies team is available, this may
be an alternative referral that would assist the patient in
further comprehensive evaluation.

Imaging
CT imaging is recommended to define the anatomy of
individual lesions and to establish the extent of disease.
A standard craniofacial CT, without contrast and with
slice thickness no greater than 3.75 mm (from top of the
head to the thyroid region), is used to evaluate for the
presence of FD in the skull base and facial bones. Historically, plain films of the craniofacial region were used but
because of the overlapping of adjacent structures, involvement of the skull base was often underreported. For
similar reasons, plain radiographs are not recommended
for diagnostic purposes for cranial or facial lesions. Dental radiographs (i.e. panorex and dental films) or a conebeam CT are appropriate to examine and help manage
lesions around the dentition. Depending on the site of
involvement, the appropriate referrals should be made
for further analysis.
The most common radiographic characteristic of craniofacial FD is a “ground-glass” appearance with a thin cortex
and without distinct borders [35]. In an ongoing study at
NIH [36], it was demonstrated that the typical characteristics of FD on CT and the natural radiographic progression
may vary from a “ground-glass” or homogenous appearance to a mixed radio-dense/radio-lucent lesion as the
patient ages (Figure 4). In pre-pubertal patients with PFD
or MAS, the lesions most often appear as homogenous,
radio-dense lesions on CT. As these patients enter the second decade of life, the FD lesions progress to a mixed
appearance, which stabilizes in adulthood but does not
resume a homogenous appearance. While the change to a
mixed radiographic appearance alone does not require
further biopsy or investigation, we recommend careful
monitoring and intermittent craniofacial CT during the
pubertal phase of the young patient. This period of change
in CT appearance coincides with case reports of increased
activity of the FD lesions either through rapid growth,
worsening facial asymmetry, malignant transformation, or
association with other pathologic, radiolucent lesions such
as an ABC and accelerated expansion [15]. Additionally, in
our collective experience, there have been young patients
who have the clinical and histologic diagnosis of a monostotic fibro-osseous lesion that are Gs mutation negative,
yet demonstrate a rapidly enlarging and predominantly
multi-loculated radiolucent appearance on CT and not the
typical indolent growth. The exact pathophysiologic
mechanism and its relationship to the variable genotype,
i.e. is this a false negative gene test or another entity, has
yet to be determined. If the patient is experiencing new
onset of symptoms or rapid enlargement at any age, an
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Figure 4 Variations in CT appearance of fibrous dysplasia based on age. A) FD in the young patient most often appears as homogenous, radiodense lesions often described as having a ground glass appearance on CT. B) As these patients enter adolescence, the FD lesions progress to a
mixed appearance which stabilizes in adulthood (C) but does not necessarily resume a homogenous appearance. This may explain the
numerous radiographic descriptions of FD in the literature such as “ground-glass”, “pagetoid”, “lytic”, and “cystic”.

updated CT is recommended as well as an immediate
referral to the appropriate specialist for further investigation and management.

Biopsy
A bone biopsy, by the appropriate surgical specialist,
should be obtained to confirm the diagnosis of FD, if the
site is amenable to biopsy. Unfortunately, the histology
does not predict the biological behavior of these lesions
[37,38]. Biopsy of FD does not specifically induce growth
of the lesion. However FD lesions may be quite vascular
and bleeding can be brisk. The surgeon should be prepared to deal with this. If the lesion is quiescent or asymptomatic, and/or in the cranial base, a biopsy may not be
possible or necessary. History, clinical examination and
the classic radiographic presentation are often adequate to
establish the diagnosis of FD.
Management by anatomic site and involvement
Facial bones

Asymmetry and swelling are the most common complaints when FD is found in the bones of the facial skeleton. Secondary deformities due to slow growing FD
include vertical dystopia (difference in the vertical position
of the eyes), proptosis, frontal bossing, facial and jaw
asymmetries or canting. The degree of facial deformity
varies, but those with MAS are the most severely affected,
particularly when associated with untreated or inadequately treated growth hormone excess (Figure 5 & 6).
The diagnosis and management of facial lesions is at
least in part based on the patient’s age and stage of skeletal maturity i.e. pediatric versus adult (skeletally
mature). In the pediatric population, of all the patients

who present for evaluation of facial swelling and asymmetry, more than half of all jaw tumors encountered are
of mesenchymal cell lineage, and of these tumors nearly
50% are fibro-osseous lesions, a significant proportion of
which are FD [37,39]. Thus, FD must be high on the
differential diagnosis for children with facial swelling
and asymmetry. The management of FD in young and
older patients is dictated by the clinical and biological
behavior of the lesion, as the histology does not provide
reliable prognostic or predictive information. There are
currently no biomarkers to predict the behavior of these
fibro-osseous lesions [37]. This is particularly concerning in pediatric patients because of the potential for
active growth, malignant transformation and association
with other tumors.
The FD lesions of the face may be described as quiescent (stable with no growth), non-aggressive (slow growing), or aggressive (rapid growth +/- pain, paresthesia,
pathologic fracture, malignant transformation, association with a secondary lesion). In the case of a quiescent
FD lesion in which the patient does not complain of
facial deformity, observation and monitoring for changes
is an acceptable treatment modality. Annual evaluations
may be adequate. The patient’s concerns and symptoms,
clinical assessment including sensory nerve testing in the
region of involvement, photographs, and facial CT should
be obtained at each visit. An annual CT may be necessary
for the first 2 years; however, the interval may be lengthened based on the clinical findings. Surgical contouring
by a maxillofacial or craniofacial surgeon is indicated if
the patient is bothered by facial disfigurement. While
complete resection may be possible in monostotic
lesions, it is unlikely to be possible in PFD or MAS), and
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Figure 5 Serial images of a woman who presented at 9-year old with MAS and extensive fibrous dysplasia complicated by growth hormone
excess. A&B) At presentation, she had a history of failure to thrive, airway obstruction, and was blind in the left eye at the time of presentation.
Due to the airway obstruction in the nose and displacement of the tongue by the mandibular lesions, she underwent extensive contouring of
the nasal bones, maxilla, and mandible with excellent results and patent airway. C-E) Over time, this patient’s lesions continued to grow but
eventually stabilized by age 17 years. F-J) The patient 5 years after the second surgery. She has improved facial contours and symmetry though
she continues to have pronounced orbital asymmetry. Her airway remains stable. She graduated magna cum laude from college.F) The 3D
model of the patient demonstrates the enlargement of the maxilla, mandible, and blockage of the nasal cavity by the FD at age 17 years. G) The
left mandible was significantly contoured to more normal proportions. H) Aggressive contouring of the left maxilla as well as the opening of the
occluded nasal cavity. I) The nasal trumpet (green) was necessary to maintain a patent passageway while healing from surgery. J&K)
Intraoperative view of the surgically removed fibrous dysplastic bone.

the surgeon must weigh the reconstruction options that
will provide the patient with the best outcome as well as
preserve the function of adjacent nerves and structures.
These patients may also require orthognathic surgery to
correct a concurrent malocclusion or facial/dental canting [40]. There is no documented contraindication for
orthognathic surgery so long as the lesions are quiescent.
Bone healing appears to be normal with conventional
rigid fixation [40]. Regular follow-up with the surgeon is
necessary to determine that there is no recurrence and
further deformity.
In patients with non-aggressive but active FD, it is ideal
to wait until the lesion becomes quiescent and the patient
has reached skeletal maturity before performing an
operation. However, in cases where the patient’s psychosocial development may be impaired due to the facial
deformity, surgical contouring and/or resection may be
warranted. The patient and family must be aware of the
potential for regrowth if the lesion cannot be resected
completely, which is often the case. In cases of PFD or
MAS where the disease is extensive, the lesions are often

not resectable. Repeat surgical contouring and extensive
debulking may be necessary to achieve acceptable facial
proportions [41]. In the future, improvement in CT imaging and software will allow for accurate surgical simulation and intraoperative navigational tools may guide the
surgeon throughout the contouring. Advanced CT software is useful for superimposition of pre- and postoperative images. These can then be compared to followup CT scans to determine stability of the result or the
presence of regrowth. Despite these new imaging technologies, there is no therapy or technology that can predict and/or prevent regrowth.
Patients with aggressive and rapidly expanding FD,
occasionally complain of new onset pain or paresthesia/
anesthesia [15]. Based on the site of involvement, the
patient may also report visual disturbances, epiphora,
impaired hearing, nasal congestion or obstruction, sinus
congestion and pain and malocclusion. We recommend
immediate evaluation by a maxillofacial surgeon, ENT, or
craniofacial surgeon and CT imaging. The etiology of this
change in behavior may not be readily identified but
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Figure 6 Serial images of the surgical approach to the woman from Figure 5 who presented at 9-year old with MAS and extensive fibrous
dysplasia complicated by growth hormone excess. A) The 3D model of the patient demonstrates the enlargement of the maxilla, mandible, and
blockage of the nasal cavity by the FD at age 17 years. B) The left mandible was significantly contoured to more normal proportions. C)
Aggressive contouring of the left maxilla as well as the opening of the occluded nasal cavity. D) The nasal trumpet (green) was necessary to
maintain a patent passageway while healing from surgery. E&F) Intraoperative view of the surgically removed fibrous dysplastic bone.
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documented causes include: associated expansile lesions
such as ABC or mucocele, malignant transformation, and
osteomyelitis. A biopsy of the area of growth is necessary
prior to surgical management. Treatment may range
from contour resection to en bloc resection depending
on the diagnosis.
In cases of an associated lesion, the management is
based on that associated lesion e.g. an ABC with FD
would warrant curettage of the ABC and contouring of
the underlying FD.
Malignant transformation of FD has been reported in
less than 1% of cases of FD [16-22]. Typically the malignancy is a sarcomatous lesion, most often osteosarcoma
but fibrosarcoma, chondrosarcoma, and malignant fibrohistiocytoma have also been reported [16,20,28,42-45].
The diagnosis may be difficult, particularly in cases of
low-grade osteosarcoma [46,47]. In such cases, immunohistochemical analysis with MDM2 and CDK4 may assist
in distinguishing FD from a malignancy as a malignancies
will often express MDM2 or CDK4 while FD will not
[48,49]. The treatment is based on the management of
the malignancy and resection with adequate margins is
necessary.
Osteomyelitis must be treated with prolonged antibiotic therapy and consultation with an infectious disease
specialist. The limited literature and our collective
experience indicate that osteomyelitis in the setting of

A
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FD is difficult to diagnose and to successfully treat
[50-54]. We have managed patients that developed osteomyelitis of the jaws after attempts at exposure and orthodontic movement of impacted teeth. It may resolve with
prolonged antibiotic treatment and pain management,
however en bloc resection of the FD lesion may be
required for refractory pain and persistent infection.

Sinuses
The sinuses may be affected by FD, with the most frequent site being the sphenoid sinus, followed by the ethmoid and maxillary sinuses (Figure 7) [55]. This is not
surprising, as the anterior cranial base is often affected in
patients with craniofacial PFD [13]. The entire sinus can
be completely obliterated by FD, yet surprisingly the incidence of sinusitis is not greater than the general population in these patients. This may be explained by the loss
of air space and Schneiderian membrane in an obliterated
sinus and the elimination of a source of infection.
Patients typically complain of nasal congestion (>34% of
those with symptoms and sinus involvement), headaches
or facial pain, recurrent sinusitis, and hyposmia. This
appears to be associated with FD in the inferior turbinate
and the subsequent hypertrophy. There appears to be a
correlation between nasal congestion and hyposmia and
the severity of disease, but a history of sinusitis and facial
pain/headaches does not correlate with the amount of

B

*

Normal face CT

FD of the right side of the face

Figure 7 Fibrous dysplasia involving the right maxillary sinus and turbinate. A) Normal facial CT without any FD for comparison. B) FD in the
right maxilla and extension into the maxillary sinus. There is also FD involvement of the right turbinate (*) that may explain the patient’s nasal
congestion.
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craniofacial disease [55]. The findings by DeKlotz and
Kim also note that growth hormone excess is associated
with more significant involvement of the sinonasal region
[55].
The management of sinus and nasal congestion
includes nasal saline spray, nasal steroid spray, antihistamines for those with seasonal allergies, and antibiotics
for suspected bacterial sinus infections. Consultation
with an otolaryngologist may be necessary for persistent
congestion and chronic sinus infections. Though there is
very little literature on the effectiveness of sinus surgery
in patients with FD sinus disease and sinus obliteration, if
surgery is indicated, we recommend waiting until the
adjacent FD is quiescent and the patient is at least in the
late teens and skeletally mature to minimize the possibility of regrowth and necessity for re-treatment. Endoscopic sinus surgery with and without image-guided
systems has become a popular approach [56-58],
although it may be necessary to combine endoscopy with
a traditional external approach [59,60]. The extent of
resection should be based on the location of the pathological bone and its proximity to important sinus structures, as radical or complete resection may not be
necessary or possible. The effectiveness of endoscopic
surgery for FD is undetermined as sinus surgery is not
commonly done in patients with FD.
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The association of other expansile lesions such as a
mucocele or ABC with sinus FD may result in rapid
growth of the combined lesion [61,62]. This is particularly concerning in areas adjacent to the skull base and
brain such as the sphenoid, ethmoid, and frontal sinuses
where access may be limited. The symptoms depend on
the adjacent involved structures such as the eye, optic
nerve, crista galli, and brain. A referral to a multidisciplinary skull base surgery center is necessary for further
evaluation and treatment.

Teeth
The dental variations in FD and the management of dental problems in patients with FD are poorly characterized.
Due to the lack of information, the dental community is
wary of treating patients with FD or MAS out of concern
for potential post-procedure complications and exacerbation of the FD lesions around the teeth [63].
Akintoye et al [64] examined 32 patients with craniofacial FD that were enrolled in the SNHFD Study. Twentythree patients had PFD/MAS and 9 had monostotic disease; this population reflected the NIH study population
with more extensive disease. In this study, 41% of the
patients had dental anomalies in general, and 28% of the
patients had the dental anomaly within FD bone. The
most common anomalies included: tooth rotation,

Figure 8 Dental anomalies seen in patients with fibrous dysplasia of the jaw bones. In a study by Akintoye et al [64], 41% of the patients with
FD had dental anomalies in general and 28% of the patients had the dental anomaly within FD bone. Adapted from reference [64]
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oligodontia, displacement, enamel hypoplasia, enamel
hypomineralization, taurodontism, retained deciduous
teeth, and attrition (Figure 8). There was no correlation
between any endocrine dysfunction or renal phosphate
wasting and enamel hypoplasia or hypomineralization,
attrition, or any of the other tooth anomalies. However,
taurodontism, a condition noted on dental radiographs
characterized by enlargement of the pulp chamber in
multi-rooted teeth, has been described in patients with
syndromes including growth hormone excess [65,66] but
never in FD/MAS. Taurodontism was noted only in the
FD patients that had 1 or more endocrinopathies. While
taurodontism does not require special dental care, it may
be an indicator of an underlying endocrinopathy associated with MAS.
The caries index scores were higher among FD patients
(Table 1). This may be attributed to the increased enamel
hypoplasia and hypomineralization or the limited dental
care these patients receive. There were no histological
abnormalities in the extracted wisdom teeth that may
explain the increased caries index scores. We recommend
more frequent dental visits, every 3-4 months. Additionally, no patients reported any complications or exacerbation of their FD lesions after dental restorations, tooth
extractions, orthodontic therapy, odontoma removal, maxillary cyst removal, or biopsy of the jaws. Among the
10 patients that received orthodontic therapy, the duration
of treatment appeared somewhat longer than conventional
cases (2-4 years in duration), the results were less than
satisfactory, and there was relapse. We recommend careful
monitoring of the post-orthodontic results in patients with
FD. Despite the extensive disease in and around the dentition in some of the patients, the arch form was predominantly maintained without significant displacement of the
teeth as compared to other benign growths.
While this may describe the natural progression of most
FD, there is clearly a subset of patients that have the clinical and histologic diagnosis of FD that have rapid growth
of the facial lesions, radiolucent changes on CT, and the
displacement of teeth from the natural arch form. While
some of these lesions have tested Gsa mutation negative,
many patients in this subset have not been genetically
characterized to determine if the absence of the Gsa mutation in the presence of a fibro-osseous lesion increases the
risk of aggressive behavior and aberrant growth. Further
Table 1
Caries Index
Fibrous dysplasia
DFT scores

Normal DMFT values*

4-17 years

2.9

1.7

≥18 years

9.6

6.6

*W.H.O country oral health profile-USA DMFT
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studies are necessary to discern the implications of the
mutation or lack of the mutation.
For patients with missing teeth, dental endosseous
implants may be considered [67]. Bone healing and integration of the implants occurs, though it may be slower
and the quality of bone is consistent with grade 3 or
4 bone as the cortex is often thin or nonexistent. In a
reported case of a 32-year old female with MAS, successful integration and loading of dental implants in the
maxilla and mandible occurred. The maxillomandibular
lesions had been quiescent for 3 years. The dental
implants were at least 15 mm in length and were functional after 5 years. The literature is limited, and it is
unclear whether there is an increased risk of implant
failure. There is also the concern that osteomyelitis may
occur in the setting of a failed implant. If implant treatment is considered, we recommend that the implant be
placed once growth of the FD lesion has subsided. Additionally, we would recommend following the principles
of implant placement and place the dental implants
after a young patient has completed growth to avoid
submerged implants and revision of the prosthesis [68].

Skull base disease
Orbit/optic nerve/sphenoid bone

Common findings associated with PFD around the eye
include proptosis, dystopia, and hypertelorism due to the
involvement of the frontal, sphenoid, and ethmoid regions
[30,69]. Less common findings include: optic neuropathy,
strabismus, lid closure problems, nasolacrimal duct
obstruction and tearing, trigeminal neuralgia and muscle
palsy with skull base involvement [70,71] (FitzGibbon,
unpublished data). There has been significant controversy
regarding the management of FD of the sphenoid bones
that encase the optic nerve, particularly in patients whose
vision is normal (Figure 9). Clinicians have assumed that
such encasement seen on CT will cause blindness because
of the proximity and compression of the optic nerve by
FD, and because of reported cases of acute loss of vision.
In one study it was reported that vision loss was the most
common neurologic complication in this disease [72].
With such concerns in mind, prophylactic decompression
of the optic nerve (“unroofing”) has been recommended
by many surgeons [23-26]. Unfortunately, decompression
may result in no improvement of vision (reported in
5-33% of cases), or worse postoperative blindness. In addition the abnormal bone tends to grow back in most cases.
The first case-control study was conducted by Lee et al
[13] to evaluate a cohort of patients with extensive cranial
base FD, and determined that observation with regular
ophthalmologic examinations in patients with asymptomatic encasement was a reasonable treatment option and
optic nerve decompression was not warranted. Though
there was statistically significant narrowing of the optic
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Figure 9 Fibrous dysplasia encasing the optic nerve compared to a normal optic canal. A-C) A patient with extensive fibrous dysplasia (FD). The
arrow indicates the optic canal. D-G) CT of a normal and uninvolved optic canal. Several CT slices through the optic canal are shown: A&D)
axial, B&E) oblique, and C&G) coronal. A case-control study by Lee et al [13] demonstrated that statistically significant narrowing of the optic
canal by FD did not result in vision loss. Thus, observation with regular ophthalmologic examinations in patients with asymptomatic encasement
was a reasonable treatment option and optic nerve decompression was not warranted. Adapted from reference [13]

canal in patients with FD, this did not result in increased
vision loss and there was no correlation between the findings on the CT and the neuro-ophthalmologic exam.
These findings were confirmed by Cutler et al. in a study
that included an analysis of the same group of subjects
after longer follow-up together with an initial analysis of
additional subjects [33]. A recent meta-analysis that
included, in addition to the most recent analysis of the
NIH SNHFD cohort, an analysis of all the published cases
of optic nerve decompression surgery, came to the same
conclusions [73]. Based on these results, we recommend
that FD in the skull base around vital structures, including
the optic nerve, should be managed according to the
clinical examination and regular diagnostic imaging and
observation is appropriate in asymptomatic patients
[13,27,33,73,74].
Once it is determined that there is FD surrounding the
optic nerve(s) and orbit, a comprehensive neuro-ophthalmologic examination should be done to establish the baseline. This should be followed by comprehensive annual

exams. The exam should concentrate on assessing for optic
neuropathy and include visual acuity, visual-field exam,
contrast sensitivity, color vision, and dilated fundus exam.
Additional examination should include pupillary examination for afferent pupil, extraocular movements, proptosis
measurement with exophthalmometry, lid closure, hypertelorism, and tear duct and puncta exam. The diagnosis of
optic neuropathy should be reserved for those with a visual
field defect or if 2 of the 3 exams (contrast sensitivity, color
vision, and fundus/disc exam) are abnormal. A new diagnostic modality, optical coherence tomography (OCT), uses
high resolution cross-sections of the optic nerve to determine the thickness of the retinal nerve fiber layer (RNFL)
[75-79]. A thin RNFL correlates with visual field changes
and evidence of optic neuropathy. This modality may be
useful for examining patients that cannot undergo a visual
field exam (such as children) or may predict visual recovery
after surgery. In the case where the RNFL may be thin
prior to surgery, it is unlikely that surgery will improve
vision while a patient with a normal RNFL may have some
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Figure 10 A representative CirrusTM optical coherence tomography (OCT) optic disc cube study (A) and serial CT scans (B) of a 9-year-old girl
with subtle left optic neuropathy and a very slowly expanding cystic lesion abutting the left optic canal. A) The numbers in the two green
circles in the RNFL (retinal nerve fiber layer) represent the single number comparison between the two eyes. Generally, the nerve fiber layer is
considered thin when it is less than about 70 microns. Note that in the RNFL Deviation Map panels the optic cup (the area within the red circle)
on the left (OS) (black arrow) is a bit larger than on the right (OD), also suggestive of axon loss. In the RNFL Thickness graph, note the
differences between the left (dashed line) and the right (solid line) in the temporal (TEMP) region (asterisk), indicating that in this region retinal
nerve fibers are thinner on the left. For children under 18 normative data for the Extracted Vertical Tomogram and the RNFL Tomogram are not
available. B) Serial coronal plane CT images at approximately the same region are shown. The expansile cystic lesion is indicated with the solid
white arrow, and the optic nerve by the dashed arrow. The findings indicate the presence of a slowly expanding lesion, the cystic, fluid-filled
nature of which was confirmed on MRI. On clinical examination, there were subtle findings of left optic neuropathy in that she performed
slightly worse on the Ishihara color test and the Pelli Robson test of contrast sensitivity in her left eye. There was no evidence of an afferent
pupil defect. Photos also demonstrated subtle temporal pallor of her left optic disc. There were no objective changes in visual acuity. She has
been followed clinically with neuro-ophthalmologic examination approximately every three months to assess for any significant progression,
which would be an indication for surgical intervention. The findings on the OCT study confirm the clinical impression of a left optic neuropathy
and are particularly useful when visual fields are not obtainable or particularly reliable (usually due to age-related inability to perform the test), as
well as an objective measure for longitudinal follow-up. The nerve fiber layer findings on OCT can also be used to predict what visual outcome
one might expect after a successful decompression surgery. If one were to find a field defect on examination, but the corresponding optic nerve
retinal nerve fiber layer was preserved on OCT testing, it would be reasonable to expect full recovery of vision after surgery. However, if there
were nerve fiber layer loss, recovery of vision would be unlikely as the findings most likely represent axons that have died back.

improvement after surgical treatment (either decompression or proptosis correction). A representative case of the
utility of the combination of OCT, clinical examination,
and imaging is shown in Figure 10.
The etiology of the visual changes and vision loss in
patients with craniofacial FD remains unclear. However,
patients with abnormal findings are more likely to have
an associated endocrinopathy, most commonly growth
hormone excess, which typically results in gradual loss

of vision, if vision loss is observed. In the cases of other
lesions such as an aneurysmal bone cyst or mucocele,
vision loss can be much more rapid. A study by Cutler
et al [33] demonstrated that 12% of patients with relatively severe craniofacial PFD had evidence of optic
neuropathy, that patients with GH excess had a higher
relative risk for complete encasement of the optic nerve
(4.1 fold), and had a higher relative risk for optic neuropathy (3.8 fold) compared to patients without GH
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excess. Preliminary findings by Glover et al demonstrated that patients with an early diagnosis and treatment of GH excess had no optic neuropathy (0 of 14
patients that were diagnosed and treated by age 18)
while 4 of 7 patients diagnosed and treated for growth
hormone excess after age 18 had optic neuropathy [80].
We strongly recommend that patients with craniofacial
PFD are evaluated for growth hormone excess or MAS
and that if endocrinopathies are present they be aggressively managed.
Patients with acute visual change or vision loss should
undergo a CT of the cranial base and immediate referral
to a neurosurgeon or craniofacial surgeon and neuroophthalmologist. Several case reports have noted the association of a new, expansile lesion near the optic nerve,
typically an aneurysmal bone cyst, and high dose glucocorticoids with immediate decompression and resection is
indicated [15]. Unfortunately, the success of surgical treatment is unknown due to the limited cases of acute vision
loss.

Auditory canal/temporal bone/cranial nerves
The temporal bone is frequently involved (>70%) in
patients with craniofacial PFD or MAS [81], while temporal bone involvement is uncommon in monostotic disease [82,83]. In a recent analysis by DeKlotz et al., despite
the high incidence of disease of the temporal bone in PFD,
nearly 85% of patients had normal or near-normal hearing;
10% had conductive hearing loss due to PFD, approximately 4% had sensorineural or mixed hearing loss (both
conductive and sensorineural), and the remainder had
hearing loss due to other, non-PFD related causes. In most
cases, the degree of hearing loss was mild (77%) and did
not correlate to the amount of disease involvement of the
temporal bone. The common causes of hearing loss
appeared to be narrowing of the external auditory canal
due to the surrounding FD (Figure 11) and fixation of the
ossicles within the epitympanum from adjacent involved
bone (Figure 12). The narrowing of the external auditory
canal may result in significant cerumen buildup. Therefore, it is recommended that regular otolaryngology exams
are performed to maintain patency in patients in whom
the external auditory canal is particularly narrowed. A rare
but potentially concerning complication is the development of a cholesteatoma, an obstruction of the canal with
cerumen and desquamated skin [83,84]. This complication
typically requires surgical intervention to relieve the
obstruction and chronic infection [82,85]. In the case of
PFD or MAS, there is concern that contouring and excision of the surrounding FD may exacerbate regrowth of
the lesion. However, only case reports have been documented noting this possibility.
We recommend a comprehensive audiology examination and ear evaluation once the temporal bone is found
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to be involved with FD. Annual hearing/audiology exams
are recommended during the active bone growth. For
external auditory canal stenosis, regular exams under
microscopy are usually required by the otolaryngologist.
Surgery for the external auditory canal is recommended
for complications such as cholesteatoma or near total ear
canal stenosis; however it may be beneficial to wait until
growth has slowed and the patient has progressed beyond
puberty.
Temporal bone involvement may also result in facial
nerve weakness or paralysis as the CN VII exits the cranium through the petrous temporal bone. This finding is
quite rare and is likely caused by the compression of the
cranial nerve within the Fallopian canal and/or the internal auditory canal [71,83,86,87]. Unfortunately, the location of the compression may be extremely difficult to
access. In case of sudden facial weakness, a high resolution cranial base or temporal bone CT is indicated. If an
expanding mass within the FD is noted, a referral to a
skull base surgeon is warranted for consideration of
surgical decompression.

Nonsurgical and adjuvant management of
craniofacial FD
While pain is common among FD patients, [88], there
are very few studies with a detailed assessment of the
symptoms and there is a need for more data relating
pain to the location and activity of disease and the effectiveness of various treatment modalities. Kelly et al [11]
examined 78 patients (35 children and 43 adults) and
found 67% complained of pain. It was not uncommon
for the pain to be undertreated; some patients required
NSAIDs with and without narcotic treatment, and
others were treated with bisphosphonates. Interestingly,
the pain scores did not correlate with the disease burden, and adults were more likely to have pain and have
more severe pain than children, suggesting there is an
age-related increase in the prevalence of pain in FD.
They also noted that, despite the high prevalence of craniofacial FD, less than 50% had pain in the craniofacial
region, in contrast to at least 50% of patients with lower
extremity disease, another high prevalence site, complained of pain. In the same study, approximately 20%
of the patients were managed with bisphosphonates and
nearly 75% reported pain relief or improvement with
this class of drugs.
The use of bisphosphonates such as alendronate, pamidronate, or zoledronic acid for craniofacial FD has been
considered for pain reduction and to reduce the rate of
growth of the lesion. In general, the clinical studies have
demonstrated mixed results on the efficacy of bisphosphonates and FD-related pain with small sample sizes
and with most studies examining all skeletal regions, not
just the craniofacial sites. Plotkin et al [89] examined 18
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Figure 11 Narrowing of the external auditory canal due to fibrous dysplasia (FD). A) A CT image of a coronal slice through the temporal bone
shows a narrowed external auditory canal (arrow) B) Narrowing of the canal is shown and can be compared to a normal canal in (C). The arrow
on the CT image (A) demonstrates narrowing of the canal. This has resulted in hearing loss. The clinical images on the right compare a canal
narrowed by FD to a normal external auditory canal.

children and adolescents with PFD or MAS and initiated
IV pamidronate therapy. They found that pain seemed to
decrease (not quantified) and serum alkaline phosphatase
and urinary N-telopeptides decreased. There were no serious side effects from the bisphosphonate use however
they noted no radiographic or histomorphometric change
or improvement of the FD lesions. Matarazzo et al [90]
reported on 13 patients with MAS who were treated with
pamidronate for 2-6 years, and found a decrease in long
bone pain, lowered fracture rate and bone turnover markers, and an increase in bone density on DEXA scan.
Chan et al [91] followed 3 children with MAS for 8-10.5
years who were age 2.5-5 years at the start of treatment
with pamidronate for MAS. They too noted a decrease in
long bone pain and fracture rate however the long bone
lesions continued to expand and grow while the facial
lesions did not expand; there was no encroachment on

the optic nerve throughout the follow-up. Chao et al [92]
noted that oral alendronate over a 6-month course
reduced intractable headaches and relieved the 3 patients
from analgesic dependence. They reported no tumor progression, however the 3 patients were adults and may not
have shown progression without the bisphosphonate
treatment. Further studies are necessary to determine the
efficacy osteoclast inhibitor therapies such as bisphosphonates or denosumab in slowing the growth of
craniofacial FD and reducing intractable craniofacial FD
pain. The variation in response between children and
adults with FD and the safety of prolonged bisphosphonate use in children also require more investigation. New
therapies are emerging that include RANK ligand inhibition (i.e. denosumab) however at this time their role in
the treatment of FD-related pain or reduction in growth
remains to be determined [93].
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FD involving the epitympanum

Figure 12 Fibrous dysplasia of the epitympanum compressing the ossicles. The arrows point to the ossicles in a normal epitympanum (A) and
in a FD-involved epitympanum (B). The crowding in the right image has resulted in hearing loss.

Conclusion
We have provided the current understanding of the biologic and clinical characteristics of FD and recommendations for the clinical management in the craniofacial
region. Most importantly, each patient may present with
variable symptoms and clinical findings, thus the care of
these patients must be customized to their needs and
sites of involvement.
Recommendations
1. Aggressively screen for and manage endocrinopathies (particularly growth hormone excess).
2. Active disease (rapid growth, new onset of pain or
paresthesia, visual or hearing changes) warrants an
immediate surgical referral and evaluation.
3. A bone biopsy should be obtained if there is any
doubt about the diagnosis. If the lesion is in a site that
cannot be biopsied due to unacceptable risks, history, clinical examination and radiographic diagnosis may be adequate for diagnosis.
4. Postpone surgical treatment of lesions until after
skeletal maturity when the lesion is quiescent.
5. Surgical resection or contouring may be warranted
prior to skeletal maturity if there are symptoms or rapid
change in the lesion, however, patients must be aware of
the risk of regrowth.
6. Potential use of adjuvant therapy such as bisphosphonates may be considered for refractory pain at the
FD site.
7. Management of patients with FD, particularly PFD
and MAS, requires a comprehensive evaluation and multidisciplinary involvement for optimal care.

Research questions
1. What are the mechanisms for changes in FD that
occur as patients age?
2. What is the mechanism and effect of growth hormone excess on the growth rate and activity of FD?
3. What are potential targeted therapies and mechanisms that can be used to treat FD?
4. What biomarkers might be useful to predict biological behavior and growth of FD lesions?
5. What potential biomarkers or predictors of transformation and associated pathologies can be developed?
6. What combined therapies will prevent recurrence
and regrowth (e.g. an operation with adjuvant bisphosphonates, interferon)?
7. What pharmacologic or molecular therapies may
reverse the effects of the abnormal gene products in FD?
8. Does the detectability of a Gs mutation in a fibroosseous lesion predict clinical behavior?
9. Is mutation testing a necessary component of FD
evaluation?
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